| Name | Title | Contact Details |
|---|---|---|
Christina Bailey |
Associate General Counsel | Profile |
Paul McInulty |
Senior Vice President, Regulatory Affairs | Profile |
Jared Freedberg |
General Counsel and Corporate Secretary | Profile |
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.
THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.
UNIConnect LC is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SGS is the world`s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 95,000 employees, SGS operates a network of over 2,400 offices and laboratories around the world.
Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, & Biotech sector.